Adenine

Evidence Level: L5

Predicted Indications: 1

Adenine

Pharmacist Assessment Report

Adenine: From an Unspecified Original Indication to Drug-Induced Osteoporosis

One-Sentence Summary

Adenine is a purine nucleobase currently marketed in Canada only as a component of red blood cell additive solutions (SAG-M / SAGM). The Health Canada records compiled for this report do not state an approved indication. The TxGNN model predicts it may be effective for drug-induced osteoporosis, but there are 0 clinical trials and only 1 publication (a rat liver toxicity study unrelated to adenine as a treatment), so the prediction is supported by the model alone.

Quick Overview

Item	Content
Original Indication	Not stated in the available Health Canada records
Predicted New Indication	Drug-induced osteoporosis
TxGNN Prediction Score	0.9916
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 1 of 2; cancelled: 1)
Number of DINs	2 (marketed: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, adenine is a naturally occurring purine base and a building block of ATP, NAD and nucleic acids. In its marketed Canadian products it serves as a component of red blood cell storage solutions, and no approved therapeutic indication was recorded in the data compiled for this report.

The only publication retrieved for the predicted indication (PMID 31026554) describes liver injury in rats caused by an herbal osteoporosis formula (Xian-Ling-Gu-Bao). It does not involve adenine as a treatment, so any link is incidental. The very high score from the TxGNN model (deep learning) (rank 14,056 overall) may reflect similarities the model learned between related diseases, not biological evidence. No credible mechanistic bridge between adenine and drug-induced osteoporosis can be established from the available data.

Clinical Trial Evidence

Currently no related clinical trials registered for drug-induced osteoporosis.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
31026554	2019	Preclinical (rat toxicology)	Journal of Ethnopharmacology	The herbal formula Xian-Ling-Gu-Bao, used for osteoporosis, caused inflammatory and oxidative stress-related liver injury in rats. Adenine is not studied as a treatment.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02386925	SAG-M	Not specified	Not specified
02444097	ADDITIVE SOLUTION SODIUM ADENINE GLUCOSE MANNITOL (SAGM)	Not specified	Not specified

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests on a high model score alone. There are no clinical trials, the single retrieved paper is unrelated to adenine therapy, and no mechanism of action or safety data are available. The Canadian products are blood-storage additive solutions, which are far removed from an osteoporosis treatment setting.

To proceed, the following is needed:

Mechanism of action data for adenine, and a plausible biological link to bone metabolism or drug-induced bone loss
Preclinical evidence (cell or animal bone models) showing a benefit of adenine
Health Canada package insert warnings and contraindications, and the approved indication text for the two DINs
Assessment of route and formulation compatibility, since the marketed products are additive solutions rather than therapeutic dosage forms
Review of safety signals, since adenine is used experimentally to induce chronic kidney disease in animal models, which raises a potential renal concern
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.